SCHEMBL13020575

SCHEMBL13020575

CO[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](n2cnc3c(NC(=O)c4ccccc4)ncnc32)O[C@@H]1CO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PRMT6 Q96LA8 1/20 0.49
ADORA3 P0DMS8 2/20 0.49
ADORA1 P30542 3/20 0.48
P2RY12 Q9H244 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GLA P06280 1/20 0.47
PMP22 Q01453 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPC1 O15118 1/20 0.47
NPY1R P25929 1/20 0.47
HTT P42858 1/20 0.47
NPY2R P49146 1/20 0.47
RAB9A P51151 1/20 0.47
SLC29A1 Q99808 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26653470 0.97 PRMT6 (0.49) MEN1KMT2APRMT6ADORA3ADORA1
SCHEMBL7032101 0.96 PRMT6 (0.51) PRMT6ADORA3ADORA1P2RY12ADORA2A
SCHEMBL8937133 0.96 PRMT6 (0.51) PRMT6ADORA3ADORA1P2RY12ADORA2A
SCHEMBL30446733 0.96 PRMT6 (0.51) PRMT6ADORA3ADORA1P2RY12ADORA2A
SCHEMBL1068383 0.94 PRMT6 (0.48) MEN1KMT2APRMT6ADORA3ADORA1
SCHEMBL13020577 0.94 PRMT6 (0.49) MEN1KMT2APRMT6ADORA3ADORA1
SCHEMBL26112399 0.92 PRMT6 (0.48) MEN1KMT2APRMT6ADORA3ADORA1
SCHEMBL29479246 0.92 PRMT6 (0.52) PRMT6ADORA3ADORA1P2RY12ADORA2A
SCHEMBL12700006 0.92 PRMT6 (0.54) MEN1KMT2APRMT6ADORA3ADORA1
SCHEMBL18048070 0.92 PRMT6 (0.48) PRMT6ADORA3ADORA1P2RY12ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE RNASEL, RNASE1, RNASEH1 MEN1 2972/4885KMT2A 1685/4885PRMT6 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.